Literature DB >> 20093141

Expression of CD45 isoforms correlates with differential proliferative responses of peripheral CD4+ and CD8+ T cells.

Iwao Seki1, Mihoko Suzuki, Nobuyuki Miyasaka, Hitoshi Kohsaka.   

Abstract

CD4(+) T cells express IL-2 receptor complexes to the same level as CD8(+) T cells when the two T cell populations were stimulated simultaneously. However, the activation of downstream signaling molecules, such as Jaks, was increased in CD8(+) T cells. Although equivalent amounts of CD45, which acts as a Jak phosphatase, was expressed on the two T cell populations, those on the CD8(+) T cells have less protein tyrosine phosphatase activity than those on the CD4(+) T cells. Furthermore, we find that different CD45 isoforms dominate in the two populations; CD45RO on proliferating CD4(+) T cells and CD45RBC on proliferating CD8(+) T cells. In addition, NIH3T3 cells expressing the CD45RBC transgene had more phosphorylated Jak1 and grew faster than those with the CD45RO transgene. Thus, the expression of specific CD45 isoforms on T cells correlates with their proliferative response to IL-2, suggesting that controlling cells expressing specific CD45 isoforms could correct excessive or insufficient immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093141     DOI: 10.1016/j.imlet.2009.12.020

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

Review 1.  Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity.

Authors:  Stephanie M Stanford; Novella Rapini; Nunzio Bottini
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

2.  Inflammasome activation is critical to the protective immune response during chemically induced squamous cell carcinoma.

Authors:  Thais Helena Gasparoto; Carine Ervolino de Oliveira; Luisa Thomazini de Freitas; Claudia Ramos Pinheiro; Juliana Issa Hori; Gustavo Pompermaier Garlet; Karen Angélica Cavassani; Roxana Schillaci; João Santana da Silva; Dario Simões Zamboni; Ana Paula Campanelli
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

3.  An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.

Authors:  Laura L Eggink; Katherine F Roby; Robert Cote; J Kenneth Hoober
Journal:  J Immunother Cancer       Date:  2018-04-17       Impact factor: 13.751

4.  Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.

Authors:  Anthony Park; Chindu Govindaraj; Sue D Xiang; Julene Halo; Michael Quinn; Karen Scalzo-Inguanti; Magdalena Plebanski
Journal:  Cancers (Basel)       Date:  2012-06-18       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.